RICHMOND, Va. – Indivior PLC (NASDAQ:LSE: INDV), a pharmaceutical company, has shared research findings emphasizing the efficacy and safety of its medication, SUBLOCADE, for individuals recovering from opioid use disorder (OUD). The data, released during Substance Abuse Prevention Month, underscore the importance of access to long-acting injectable treatments like SUBLOCADE in supporting long-term recovery.
Recent studies, including a phase 3 clinical trial published in the Harm Reduction Journal, indicate that SUBLOCADE’s 300 mg dose significantly increases opioid abstinence among users who inject opioids. Results from the Community Long-Acting Buprenorphine (CoLAB) Study, detailed in the International Journal of Drug Policy, also show sustained improvements in abstinence and quality of life for up to 96 weeks.
Access to medication-assisted treatment (MOUD) remains a challenge, as research published in American Health & Drug Benefits found that telemedicine has been a key method to overcome barriers, particularly during the COVID-19 pandemic. A review in Corrections Today highlights the disparity in MOUD access between the general public and incarcerated individuals, with stigma and informed consent as significant barriers.
Dr. Christian Heidbreder, Chief Scientific Officer at Indivior, stated that the collective evidence highlights the importance of access to MOUDs, like SUBLOCADE, in reducing adherence barriers and improving recovery outcomes. Indivior is committed to advancing patient understanding, evidence-based practices, and overcoming stigma.
SUBLOCADE is an injectable form of buprenorphine designed to treat moderate to severe OUD as part of a comprehensive treatment plan including counseling and psychosocial support. It is available only through a restricted program due to the risks associated with intravenous administration.
Despite the nearly 6 million Americans aged 12 or older with OUD in 2023, only about 18% received MOUD treatment. Indivior’s efforts aim to address this treatment gap and support recovery for individuals with OUD.
This article is based on a press release statement.
In other recent news, pharmaceutical company Indivior has seen a series of noteworthy developments. Indivior reported its third-quarter results, which met revenue expectations and exceeded bottom-line projections, leading Piper Sandler to increase its price target for the company’s shares to $16.00. Despite some underperformance in its C&V business segment, Piper Sandler maintains an Overweight rating on Indivior’s stock.
Indivior also revised its full-year 2024 revenue projections for its product, Sublocade, due to increased competition. The company now anticipates revenues for Sublocade to range between $725 million and $745 million. Craig-Hallum, however, has expressed belief in the company’s resilience and potential growth, despite reducing Indivior’s stock price target from $24.00 to $20.00.
The U.S. Food and Drug Administration (FDA) has granted Priority Review for a Prior Approval Supplement (PAS) for Sublocade, potentially improving treatment options. Indivior also secured an $8.7 million order from the Biomedical Advanced Research and Development Authority (BARDA) for Opvee, a medication designed to reverse opioid overdoses. These are recent developments investors should consider when evaluating Indivior’s financial health.
InvestingPro Insights
As Indivior PLC (NASDAQ:LSE: INDV) continues to make strides in addressing the opioid use disorder treatment gap, investors may find value in examining the company’s financial health and market performance. According to InvestingPro data, Indivior’s revenue growth stands at 13.44% for the last twelve months as of Q3 2024, aligning with the company’s efforts to expand access to its SUBLOCADE treatment.
The company’s gross profit margin of 82.4% for the same period suggests strong pricing power for its pharmaceutical products, which could be attributed to the unique positioning of SUBLOCADE in the OUD treatment market. This high margin may provide Indivior with the financial flexibility to invest in research and development, as well as in initiatives to overcome barriers to treatment access.
InvestingPro Tips highlight that Indivior’s net income is expected to grow this year, which could be a positive sign for investors considering the company’s focus on expanding its treatment offerings. Additionally, analysts predict that the company will be profitable this year, potentially reflecting the market’s confidence in Indivior’s business model and growth strategy.
It’s worth noting that InvestingPro offers 11 additional tips for Indivior, providing a more comprehensive analysis for investors interested in the company’s prospects. These insights could be particularly valuable given the company’s position in the evolving landscape of OUD treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
